search
Back to results

Promote Health With Digital Tools Among Adults With Type 2 Diabetes/Prediabetes and/or Hypertension (DigiCare4You)

Primary Purpose

Type 2 Diabetes, PreDiabetes, Hypertension

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
mHealth intervention
Standard care
Sponsored by
Harokopio University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring community, primary healthcare, families, m-health application, diabetes, hypertension, screening, lifestyle intervention, self-management, people-centred care, scaling-up

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: People who have their permanent residence within the prefecture/region of the relevant facility participating in the clinical study. People having children at primary and/ or secondary education. People who are physically and mentally able to provide their informed consent to participate. People with a FINDRISC ≥10 People with a fasting plasma glucose (FPG) ≥ 100 mg/dL and /or glycated hemoglobin (HbA1c) ≥ 5.7% Exclusion Criteria: People suffering from a health condition where adherence to the intervention will be contraindicated or improbable. People unable to express a free and informed consent for medical and/or psychological conditions, mental incapacity.

Sites / Locations

  • Universiteti i MjekësisëRecruiting
  • Medical University of VarnaRecruiting
  • Harokopio UniversityRecruiting
  • Universidad de ZaragozaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Pre-diabetes group, mHealth intervention

Diabetes group, mHealth intervention

Prediabetes group, control

Diabetes group, control

Arm Description

Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care

Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care

Participants will receive standard care, including lifestyle recommendations

Participants will receive standard care, including lifestyle recommendations

Outcomes

Primary Outcome Measures

Change from Baseline in fasting plasma glucose [FPG] at 12 months (1st follow-up)
Fasting plasma glucose [FPG] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Change from Baseline in fasting plasma glucose [FPG] at 24 months (2nd follow-up)
Fasting plasma glucose [FPG] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Change from Baseline in glycated hemoglobin [HbA1c] at 12 months (1st follow-up)
Glycated hemoglobin [HbA1c] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Change from Baseline in glycated hemoglobin [HbA1c] at 24 months (2nd follow-up)
Glycated hemoglobin [HbA1c] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.

Secondary Outcome Measures

Change from Baseline in blood pressure [BP] at 12 months (1st follow-up)
Blood pressure [BP] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Change from Baseline in blood pressure [BP] at 24 months (2nd follow-up)
Blood pressure [BP] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Change from Baseline in body weight [BW] at 12 months (1st follow-up)
Body weight [BW] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Change from Baseline in body weight [BW] at 24 months (2nd follow-up)
Body weight [BW] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Change from Baseline in waist circumference [WC] at 12 months (1st follow-up)
Waist circumference [WC] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Change from Baseline in waist circumference [WC] at 24 months (2nd follow-up)
Waist circumference [WC] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.

Full Information

First Posted
November 28, 2022
Last Updated
December 5, 2022
Sponsor
Harokopio University
Collaborators
Medical University of Varna, Centre for Research and Technology Hellas, University of Medicine, Tirana, La Trobe University, National and Kapodistrian University of Athens, NYU Grossman School of Medicine, University Ghent, Universidad de Zaragoza, PRIVANOVA SAS, Monash University, METEDA SRL, Baker Heart and Diabetes Institute, Sant'Anna School of Advanced Studies, International Diabetes Federation, STICHTING INTERNATIONAL FOUNDATION FORINTEGRATED CARE, EUROPEAN UNION'S HORIZON 2020 RESEARCH AND INNOVATION PROGRAMME (Project Number: 945246)
search

1. Study Identification

Unique Protocol Identification Number
NCT05648383
Brief Title
Promote Health With Digital Tools Among Adults With Type 2 Diabetes/Prediabetes and/or Hypertension
Acronym
DigiCare4You
Official Title
An Intersectoral Innovative Solution Involving DIGItal Tools, Empowering Families and Integrating Community CARE Services for the Prevention and Management of Type 2 Diabetes and Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2022 (Actual)
Primary Completion Date
February 28, 2025 (Anticipated)
Study Completion Date
February 28, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Harokopio University
Collaborators
Medical University of Varna, Centre for Research and Technology Hellas, University of Medicine, Tirana, La Trobe University, National and Kapodistrian University of Athens, NYU Grossman School of Medicine, University Ghent, Universidad de Zaragoza, PRIVANOVA SAS, Monash University, METEDA SRL, Baker Heart and Diabetes Institute, Sant'Anna School of Advanced Studies, International Diabetes Federation, STICHTING INTERNATIONAL FOUNDATION FORINTEGRATED CARE, EUROPEAN UNION'S HORIZON 2020 RESEARCH AND INNOVATION PROGRAMME (Project Number: 945246)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The DigiCare4You project will use digital tools for early screening, prevention and management of type 2 diabetes (T2D) and hypertension (HTN). An implementation study will be conducted, targeting more than 10,000 families in two Middle Income Countries (Albania and Bulgaria) and two High Income Countries (Greece and Spain), considering vulnerable groups. Schools will be used as an entry point to the community. Building on an existing procedure for children's periodic growth assessment, conducted by school nurses or in collaboration with local community health centers, parents/ caregivers will be screened via a non-invasive self-reported digital screening tool. Those identified at high risk for T2D will be referred for glycaemia testing (fasting plasma glucose and glycated hemoglobin, HbA1c), as well as blood pressure (BP) measurements, at local community health centers. Parents/ caregivers confirmed to have pre-diabetes or diabetes (and possibly high BP) will be invited to join a mHealth self-management intervention coordinated by the community healthcare workforce. The goal of this intervention is to involve high-risk adults in the treatment process and decision-making on personalized behavioral goals (e.g. diet, physical activity, smoking, alcohol, medication compliance) that meet their needs, and ultimately improve the health status of parents/caregivers, as well as the lifestyle of the entire family.
Detailed Description
The rising burden of diabetes poses important public health challenges to health systems nowadays. The age-standardized rates of diabetes prevalence have stabilized in many European countries in recent years, especially in the Nordic countries, but they have gone up in Southern, Eastern and Central EU countries. However, in the vast majority of countries, national diabetes plans are poorly (or not) implemented and underfunded and although T2D is preventable, its prevalence is expected to reach 66 million by 2030, and 68 million by 2045. According to the World Health Organization (WHO)'s "Framework on integrated people-centred health services", integrated people-centred health services put people and communities, not diseases, at the centre of health systems, and empower people to take charge of their own health rather than being passive recipients of services. People-centred care is one of the main goals of health systems, and it is oriented towards the needs of people and their involvement in the treatment process and decision-making. This is expected to result in better care as experienced by people, less inequality, health promotion, better disease prevention, and treatments targeted to people's needs. Health system transition to people-centred care requires empowering citizens and integration of services. The growing digital transformation of health and care offers great opportunity to achieve this transition. Innovative solutions involving digital tools have the potential to improve people-centred care through self-management, goal orientation and shared decision-making. The DigiCare4You project is in line with the WHO's conceptual framework, and is oriented to health promotion and disease prevention through empowering families and integrating care services in local communities to deliver people-centred care for the prevention and management of T2D and HTN. Ultimately, the DigiCare4You project aims to involve high-risk adults in the treatment process and decision-making on personalized behavioral goals (e.g. diet, physical activity, smoking, alcohol, medication compliance) that meet their needs. The DigiCare4You project proposes a people-centered health service model to prevent and manage T2D and HTN by using the existing resources and adding digital tools for empowering both the existing healthcare workforce and the healthcare recipients. The proposed model aims to integrate two fragmented primary care services, i.e., (a) the children's growth and development monitoring and (b) the early screening and prevention of T2D and HTN. The first one is implemented across all countries in Europe from birth through late adolescence, it includes a physical examination (eye, oral and hearing), anthropometric measurements (weight and height), vaccination evaluation and a brief family medical history, and it is usually linked with the school (primary and secondary education). The latter primary care service related to the screening and prevention of T2D and HTN among the adult population in Europe is poorly or not implemented at all despite the fact that the majority of European countries have made progress towards developing a national plan addressing diabetes specifically or in an overarching plan for non-communicable diseases (NCDs). Integrating the existing children's' growth assessment procedure with the adult screening procedure for NCDs, can help identify and treat parents (and eventually families) at risk for T2D. Specifically, the proposed model, called DigiCare4You solution, consists of two core components: a) a two-stage systematic screening procedure, and (b) a mHealth, community-based intervention. The two-stage screening procedure will be implemented using schools as the entry point to the community in order to reach as many parents with children at primary or secondary education as possible, and assess their risk for T2D and/or HTN. First, high risk parents will be identified through a digitalized non-invasive screening procedure (1st stage screening), using a self-reported questionnaire, the Finnish Diabetes Risk Score (FINDRISC). Those parents with a FINDRISC ≥10 will be referred to glycaemia testing (i.e., fasting plasma glucose [FPG], and glycated hemoglobin [HbA1c]) according to the national guidelines in each country) and blood pressure evaluation (2nd stage screening). Parents confirmed to have pre-diabetes or diabetes will be invited to join the self-management intervention including access to the DigiCare4You mHealth applications. The DigiCare4You mHealth applications will assist users make personalised decisions with respect to behavioral changes (e.g., diet tracking and meal planning, physical activity, sleep quantity), medication use (if applicable), scheduling/reminding re-examination visits and prospectively monitoring their health outcomes. Last but not least, these applications will enable direct communication between the users and their healthcare providers through feedback messages and reports, including lab results. DigiCare4You acknowledges the differences in health and care systems across Europe and considering the vulnerable and underserved groups, will be adapted and implemented in two Middle-income countries (MICs), Albania and Bulgaria, and two High-income countries (HICs), Greece and Spain, all with high prevalence of T2D and HTN and weak primary healthcare systems. Furthermore, in all countries, both municipalities of medium-high and low socioeconomic status (SES) areas (with low literacy levels, high rates of unemployment and large proportions of immigrants) will also be included. Overall, the DigiCare4You solution will ensure that even the most underserved parts of the community will be reached and any potential barrier towards achieving equal access for all will be tackled. This approach will allow the evaluation of the success and validity of the solution among MICs and HICs, and among the underserved and marginalized populations within countries. Therefore, if the DigiCare4You solution will be proven to be equally effective among high and low-SES groups, this will ensure that the uptake of the solution at large scale will promote equity in health and easy access to primary healthcare services for the overall population. A hybrid II implementation study will be designed to implement and evaluate the DigiCare4You solution, comparing the mHealth intervention (intervention arm) with the existing standard care (control arm). In all four countries, a 1:1 cluster-randomized design will be followed, randomly allocating municipalities (therefore the schools, the local community health centers and the families within each municipality) to either the intervention or the control arm. DigiCare4You intervention will have a two-year duration and all measurements for the impact and outcome evaluation will take place at baseline and at 12- and 24-months follow-ups, while the process evaluation at participant, school and community level will be ongoing throughout the implementation period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, PreDiabetes, Hypertension
Keywords
community, primary healthcare, families, m-health application, diabetes, hypertension, screening, lifestyle intervention, self-management, people-centred care, scaling-up

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
992 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pre-diabetes group, mHealth intervention
Arm Type
Experimental
Arm Description
Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
Arm Title
Diabetes group, mHealth intervention
Arm Type
Experimental
Arm Description
Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
Arm Title
Prediabetes group, control
Arm Type
Active Comparator
Arm Description
Participants will receive standard care, including lifestyle recommendations
Arm Title
Diabetes group, control
Arm Type
Active Comparator
Arm Description
Participants will receive standard care, including lifestyle recommendations
Intervention Type
Behavioral
Intervention Name(s)
mHealth intervention
Intervention Description
Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
Intervention Type
Behavioral
Intervention Name(s)
Standard care
Intervention Description
Participants will receive standard care, including lifestyle recommendations.
Primary Outcome Measure Information:
Title
Change from Baseline in fasting plasma glucose [FPG] at 12 months (1st follow-up)
Description
Fasting plasma glucose [FPG] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Time Frame
Baseline and 12 months (1st follow-up)
Title
Change from Baseline in fasting plasma glucose [FPG] at 24 months (2nd follow-up)
Description
Fasting plasma glucose [FPG] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Time Frame
Baseline and 24 months (2nd follow-up)
Title
Change from Baseline in glycated hemoglobin [HbA1c] at 12 months (1st follow-up)
Description
Glycated hemoglobin [HbA1c] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Time Frame
Baseline and 12 months (1st follow-up)
Title
Change from Baseline in glycated hemoglobin [HbA1c] at 24 months (2nd follow-up)
Description
Glycated hemoglobin [HbA1c] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Time Frame
Baseline and 24 months (2nd follow-up)
Secondary Outcome Measure Information:
Title
Change from Baseline in blood pressure [BP] at 12 months (1st follow-up)
Description
Blood pressure [BP] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Time Frame
Baseline and 12 months (1st follow-up)
Title
Change from Baseline in blood pressure [BP] at 24 months (2nd follow-up)
Description
Blood pressure [BP] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Time Frame
Baseline and 24 months (2nd follow-up)
Title
Change from Baseline in body weight [BW] at 12 months (1st follow-up)
Description
Body weight [BW] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Time Frame
Baseline and 12 months (1st follow-up)
Title
Change from Baseline in body weight [BW] at 24 months (2nd follow-up)
Description
Body weight [BW] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Time Frame
Baseline and 24 months (2nd follow-up)
Title
Change from Baseline in waist circumference [WC] at 12 months (1st follow-up)
Description
Waist circumference [WC] is measured in participants with T2D and in participants with prediabetes at 12 months (1st follow-up) from baseline.
Time Frame
Baseline and 12 months (1st follow-up)
Title
Change from Baseline in waist circumference [WC] at 24 months (2nd follow-up)
Description
Waist circumference [WC] is measured in participants with T2D and in participants with prediabetes at 24 months (2nd follow-up) from baseline.
Time Frame
Baseline and 24 months (2nd follow-up)
Other Pre-specified Outcome Measures:
Title
Change form Baseline in the BMI z-score of children at 12 months (1st follow-up)
Description
Although children will not directly receive any intervention, their BMI z-score will be calculated at 12 months (1st follow-up) of the intervention in parents with T2D and in parents with prediabetes. Change = (Month 12 score - Baseline score)
Time Frame
Baseline and 12 months (1st follow-up)
Title
Change form Baseline in the BMI z-score of children at 24 months (2nd follow-up)
Description
Although children will not directly receive any intervention, their BMI z-score will be calculated at 24 months (2nd follow-up) of the intervention in parents with T2D and in parents with prediabetes. Change = (Month 24 score - Baseline score)
Time Frame
Baseline and 24 months (2nd follow-up)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: People who have their permanent residence within the prefecture/region of the relevant facility participating in the clinical study. People having children at primary and/ or secondary education. People who are physically and mentally able to provide their informed consent to participate. People with a FINDRISC ≥10 People with a fasting plasma glucose (FPG) ≥ 100 mg/dL and /or glycated hemoglobin (HbA1c) ≥ 5.7% Exclusion Criteria: People suffering from a health condition where adherence to the intervention will be contraindicated or improbable. People unable to express a free and informed consent for medical and/or psychological conditions, mental incapacity.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yannis Manios, Professor
Phone
2109549156
Ext
+30
Email
manios@hua.gr
First Name & Middle Initial & Last Name or Official Title & Degree
Christina Mavrogianni, Dr
Phone
2109549353
Ext
+30
Email
cmavrog@hua.gr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yannis Manios, Professor
Organizational Affiliation
Harokopio University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universiteti i Mjekësisë
City
Tirana
State/Province
Rruga E Dibrës
ZIP/Postal Code
AL1005
Country
Albania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florian Toti, Professor
Phone
5692051742
Ext
+35
Email
floritoti@yahoo.it
Facility Name
Medical University of Varna
City
Varna
ZIP/Postal Code
9002
Country
Bulgaria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natalya Usheva, Assoc. Prof.
Phone
952677164
Ext
+35
Email
nataly_usheva@hotmail.com
Facility Name
Harokopio University
City
Athens
State/Province
Attica
ZIP/Postal Code
17676
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yannis Manios, Professor
Phone
2109549156
Ext
+30
Email
manios@hua.gr
First Name & Middle Initial & Last Name & Degree
Christina Mavrogianni, Dr
Phone
2109549353
Ext
+30
Email
cmavrog@hua.gr
Facility Name
Universidad de Zaragoza
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luis A. Moreno, Professor
Phone
976761000
Ext
+ 34
Email
lmoreno@unizar.es

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD) will be shared with the project partners and third parties.Although a preliminary version of the Data Management Plan has been developed, there are still a few points to be finalized, including the time frame with respect to data availability, the access criteria regarding how requests for information will be reviewed, and if a web address will be used to share IPD.
IPD Sharing Time Frame
This has not been decided yet.
IPD Sharing Access Criteria
For the duration of the project, data will be stored in a Secure Cloud-Based Repository, managed by the Project Coordinator who will authorize access to project partners' staff; when partners or partners' staff leave the project, the access to the repository will be disabled. Third parties will be granted access to the data for research purposes, including validation of the results presented in scientific publications.
Citations:
PubMed Identifier
32164646
Citation
Manios Y, Mavrogianni C, Lambrinou CP, Cardon G, Lindstrom J, Iotova V, Tankova T, Civeira F, Kivela J, Jancso Z, Shadid S, Tsochev K, Mateo-Gallego R, Rado S, Dafoulas G, Makrilakis K, Androutsos O; Feel4Diabetes-study group. Two-stage, school and community-based population screening successfully identifies individuals and families at high-risk for type 2 diabetes: the Feel4Diabetes-study. BMC Endocr Disord. 2020 Mar 12;20(Suppl 1):12. doi: 10.1186/s12902-019-0478-9.
Results Reference
result
PubMed Identifier
30207513
Citation
Manios Y, Androutsos O, Lambrinou CP, Cardon G, Lindstrom J, Annemans L, Mateo-Gallego R, de Sabata MS, Iotova V, Kivela J, Martinez R, Moreno LA, Rurik I, Schwarz P, Tankova T, Liatis S, Makrilakis K. A school- and community-based intervention to promote healthy lifestyle and prevent type 2 diabetes in vulnerable families across Europe: design and implementation of the Feel4Diabetes-study. Public Health Nutr. 2018 Dec;21(17):3281-3290. doi: 10.1017/S1368980018002136. Epub 2018 Sep 12.
Results Reference
result
PubMed Identifier
12610029
Citation
Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003 Mar;26(3):725-31. doi: 10.2337/diacare.26.3.725.
Results Reference
result
PubMed Identifier
30796939
Citation
Mavrogianni C, Lambrinou CP, Androutsos O, Lindstrom J, Kivela J, Cardon G, Huys N, Tsochev K, Iotova V, Chakarova N, Rurik I, Moreno LA, Liatis S, Makrilakis K, Manios Y; Feel4Diabetes-study group. Evaluation of the Finnish Diabetes Risk Score as a screening tool for undiagnosed type 2 diabetes and dysglycaemia among early middle-aged adults in a large-scale European cohort. The Feel4Diabetes-study. Diabetes Res Clin Pract. 2019 Apr;150:99-110. doi: 10.1016/j.diabres.2019.02.017. Epub 2019 Feb 20.
Results Reference
result
PubMed Identifier
25581147
Citation
Oldenburg B, Taylor CB, O'Neil A, Cocker F, Cameron LD. Using new technologies to improve the prevention and management of chronic conditions in populations. Annu Rev Public Health. 2015 Mar 18;36:483-505. doi: 10.1146/annurev-publhealth-031914-122848. Epub 2015 Jan 12.
Results Reference
result
PubMed Identifier
28339628
Citation
O'Neil A, Cocker F, Rarau P, Baptista S, Cassimatis M, Barr Taylor C, Lau AYS, Kanuri N, Oldenburg B. Using digital interventions to improve the cardiometabolic health of populations: a meta-review of reporting quality. J Am Med Inform Assoc. 2017 Jul 1;24(4):867-879. doi: 10.1093/jamia/ocw166.
Results Reference
result
Links:
URL
https://digicare4you.eu/
Description
DigiCare4You link website

Learn more about this trial

Promote Health With Digital Tools Among Adults With Type 2 Diabetes/Prediabetes and/or Hypertension

We'll reach out to this number within 24 hrs